Last reviewed · How we verify
Galvus (vildagliptin)
Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), allowing incretin hormones to accumulate and stimulate insulin secretion in response to glucose.
Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), allowing incretin hormones to accumulate and stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Galvus (vildagliptin) |
|---|---|
| Sponsor | Korea University Anam Hospital |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By blocking DPP-4 enzyme activity, vildagliptin prevents the degradation of GLP-1 and GIP, two incretin hormones that enhance glucose-dependent insulin secretion from pancreatic beta cells. This mechanism lowers blood glucose levels in a glucose-dependent manner, reducing hypoglycemia risk. The drug is effective as monotherapy or in combination with other antidiabetic agents.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Headache
- Nasopharyngitis
- Dizziness
- Hypoglycemia (when combined with other agents)
Key clinical trials
- A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome (PHASE2, PHASE3)
- Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (PHASE2)
- Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors (PHASE4)
- Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia (PHASE2)
- The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients (PHASE1, PHASE2)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |